Miguel Escobar, MD

Professor of Medicine, Medical Director
University of Texas Health Science Center of Houston, McGovern Medical School, Gulf States Hemophilia and Thrombophilia Center, Houston, Texas

Dr Escobar is tenured Professor of Internal Medicine and Pediatrics at the University of Texas, MD Anderson Cancer Center and the McGovern Medical School in Houston, Division of Hematology. He is the Director of the Gulf States Hemophilia Center, the Research Center at the University and the Anticoagulation Services at the Memorial Hermann Hospital in Houston.
Dr Escobar is a member of the World Federation of Hemophilia Board of Directors and a Co-Chair of the Scientific and Standardization Subcommittee on FVIII/FIX & rare coagulation disorders for the ISTH. Dr Escobar has been involved in many clinical studies, resulting in a range of publications

Miguel A. Escobar, M.D.
Professor of Medicine and Pediatrics
Divison of Hematology
University of Texas Health Science Center at Houston
Gulf States Hemophilia & Thrombophilia Center

Presentation(s):

• PB0167 - Emicizumab use in Acquired von Willebrand Disease: Single Case Report

  Sunday, July 10, 2022
  6:30 PM – 7:30 PM

• SSC 13.08 - Q&A

  Monday, July 11, 2022
  5:24 PM – 5:34 PM

• PB0665 - A Case of Discrepant One-stage and Chromogenic Factor VIII Activity Assay in a Patient with a Hemizygous Arg550His Mutation in the F8 Gene

  Monday, July 11, 2022
  6:30 PM – 7:30 PM

• PB0705 - East Texas Bleeding Disorder – A Novel Bleeding Disorder

  Monday, July 11, 2022
  6:30 PM – 7:30 PM

• PB1174 - Eptacog beta for resolution of bleeding episodes in patients with hemophilia A or B with inhibitors: Efficacy and safety according to inhibitor titer

  Tuesday, July 12, 2022
  6:30 PM – 7:30 PM

• VPB1189 - ATHN 16: Safety of Coagulation Factor VIIa (recombinant)-jncw for the Treatment of Bleeding Events in Patients with Congenital Hemophilia A or B with Inhibitors, with or without Prophylactic Treatment

  Tuesday, July 12, 2022
  6:30 PM – 7:30 PM